ROMISET 250

Romiset 250mcg Injection, containing the active ingredient Romiplostim, is categorized as a platelet-stimulating agent. It is used to treat immune primary thrombocytopenia (ITP), a condition where the body’s immune system mistakenly attacks and destroys its own platelets, leading to low platelet counts. This drug is primarily prescribed for adults and children aged 18 years and over with ITP when other treatments, such as immunoglobulins, corticosteroids, or splenectomy (surgical removal of the spleen), have not been effective in increasing platelet counts.

This medication is contraindicated in individuals with known hypersensitivity or allergic reactions to other medicines produced by DNA technology using the microorganism Escherichia coli (E. coli). Before receiving this injection, it is crucial to inform your physician about conditions such as liver problems, cancer, recent surgery, smoking habits, and if you are taking birth control pills. These factors can influence the safety and effectiveness of the medication, and your physician needs this information to determine if Romiset 250mcg Injection is appropriate for you or if any treatment adjustments are necessary.

During treatment with Romiset 250mcg Injection, your physician will regularly monitor your blood tests to check for any abnormalities that might indicate changes in the bone marrow. This is important because the drug has been associated with significant bone marrow changes. If abnormalities are detected, your doctor will assess their importance and decide on the appropriate course of action, which may include continuing or discontinuing the treatment. Romiset 250mcg Injection is not recommended for pregnant patients unless specifically indicated by your doctor. You must inform your physician if you are pregnant, suspect you are pregnant, or are planning for pregnancy before starting the treatment. It is unknown whether this drug is present in human milk, therefore breastfeeding should be avoided